Scalable throughput from microLiters to Liters
NanoGenerator® Synthesis System
Nanoparticle Formulation & Preparation
NanoGenerator® is a high-performance nanoparticles synthesis system for the formulating and preparing nanoparticles, including lipid nanoparticles (LNP), liposomes, PLGA, etc. Lipid nanoparticle synthesis is the process of creating lipid nanoparticles, which are a type of drug delivery system that encapsulate therapeutic molecules in a lipid shell. LNP synthesis plays a crucial role in drug delivery and therapeutics.
NanoGenerator produces nanoparticles with improved size uniformity and a lower polydispersity index (PDI). It offers scalable production, ranging from ultra-low volumes of 0.1 mL for early-stage screening to large-scale batch production of hundreds of liters, enabling seamless, continuous GMP-compliant manufacturing.
Path from Discovery to Commercialization
NanoGenerator system offers controllable and reproducible mixing conditions, ensuring the accurate synthesis of LNPs through its scalable architecture found in the entire NanoGenerator product line.
This architecture facilitates the seamless transfer of crucial process parameters, guaranteeing consistent critical quality attributes (CQAs) as one transitions from discovery and screening, process development to GMP production and commercial manufacturing for a wide range of applications, such as mRNA LNP vaccine development.
NanoGenerator Models
Discovery & Screening
Pre-Clinical
Clinical & Commercialization
System Benefits
High Performance & Efficiency
-
Tunable size (40-200nm)
-
Low PDI
-
High encapsulation efficiency
Automation & QC
-
Automated workflow
-
Real-time data monitoring & recording
Open Platform
-
LNP reagents
-
Microfluidic mixer chips
Cost Effective
-
Affordable system
-
Low cost consumables
-
Minimum maintenance
Scalable & Reproducible
-
Scale-up and minimum process development
-
Direct transfer from clinical development to commercial manufacturing
-
Reproducible manufacturing
Custom Design & Service
-
Custom design & OEM
-
Research collaboration
-
On-site 3Q installation & qualification (optional)
Cost-effective, Scalable and Reproducible
Discovery & Screening
PreciGenome's NanoGenerator platform's precise control of parameters ensures consistent critical quality attributes, such as particle size, throughout the entire development and manufacturing process. This guarantees speed, cost-effectiveness, and reliability at every stage.
Working Principle
Payloads
Genetic medicines consist of DNA and RNA, which serve as therapeutic agents when delivered into the body. These genetic materials act as versatile payloads, and can synthesized and manufactured in large scale in the lab. Moreover, they’ve undergone clinical validation. There are a variety of types of genetic medicine payloads, each tailored to specific advantages and capable of treating different types of diseases
mRNA/siRNA
Proteins and peptides
DNA
Small molecules
Carriers
Utilizing Nanogenerator technology, develop a diverse array of nanoparticle formulations, each varying in size, payload, and excipient characteristics.
Payloads
Carrier Materials
-
Nucleic Acid
-
Peptides and Proteins
-
Ionizable lipids/Cationic lipids
-
Phospholipids
-
Cholesterol
-
PEG-Lipids
-
Nucleic Acid
-
Peptides and Proteins
-
Small Molecules
-
Imaging Contrast Agents
-
Phospholipids
-
Cholesterol
-
PEG-Lipids
Polymer Nanoparticles
-
Nucleic Acid
-
Peptides and Proteins
-
Small Molecules
-
Imaging Contrast Agents
-
Poly-lactides (such as PLGA)
-
Block copolymers (such as PEG-b-PLGA)
-
Polysaccharides (such as chitosan, cellulose)
Emulsions
-
Small Molecules
-
Imaging Contrast Agents
-
Triolein/POPC
-
Oil
-
Surfactant
Exosomes
-
Nucleic Acid
-
Peptides and Proteins
-
Small Molecules
-
Natural cell-derived lipids
-
Natural cell-derived proteins
-
Additional synthetic lipids
-
Additional synthetic biomolecules
System Applications
Gene Therapy
Genetic drugs, including small interfering RNA (siRNA), mRNA, or plasmid DNA, hold promise for treating a wide array of diseases by either suppressing harmful genes, producing therapeutic proteins, or employing gene-editing techniques. Currently, lipid nanoparticle (LNP) systems stand at the forefront among non-viral delivery methods, enabling the clinical utilization of genetic drugs.
Vaccines
Lipid nanoparticle has played a pivotal role in expediting the development of vaccines, as demonstrated by Pfizer and Moderna in the COVID-19 pandemic response. It allows for precise and high-throughput screening of potential vaccine candidates. The technology facilitates rapid testing, antigen formulation, and optimization of vaccine delivery systems.
Cell Therapy
Cell Therapies entail the transformation of cells, commonly immune cells, obtained either from the patient (autologous) or a compatible donor (allogeneic). These modified cells undergo isolation, amplification, and are later reintroduced into the patient. Lipid Nanoparticles (LNPs) present a versatile approach to cell reprogramming, facilitating the transfer of RNA responsible for protein expression or gene editing.
(Lean more gene editing)
Other Areas
